Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Xenon Pharmaceuticals presented positive data from the Phase 3 X-TOLE2 study on azetukalner, a potential new treatment for focal onset seizures, at the 2026 American Academy of Neurology Annual Meeting. The study showed significant reductions in seizure frequency and increasing rates of seizure freedom over time.
Xenon Pharmaceuticals presented positive data from the Phase 3 X-TOLE2 study on azetukalner at the 2026 American Academy of Neurology Annual Meeting. Azetukalner showed a 53.2% reduction in monthly seizure frequency compared to 10.4% for placebo. Long-term data from the X-TOLE open-label extension study at 48 months showed nearly 40% of participants achieving at least 12 months of seizure freedom. The data suggest azetukalner could be a preferred medication for addressing uncontrolled seizures. Xenon plans to submit a New Drug Application to the FDA in the third quarter of 2026.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.